A recent study in Crohn’s disease patients has shown changes in the microbiota composition after TNF-α inhibitor (adalimumab) treatment, with recovery of phylogroups (Firmicutes, Bacteroides and Actinobacteria) and decrease of E. coli during treatment63. The gene discussed is TNF; the disease is Crohn disease.